Early camizestrant therapy keeps advanced breast cancer in check

[News]

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains quality of life in patients with ESR1-mutated, hormone receptor-positive advanced breast cancer. The proactive, biomarker-guided approach allows earlier intervention and may redefine standard care.

More... (https://www.news-medical.net/news/20250603/Early-camizestrant-therapy-keeps-advanced-breast-cancer-in-check.aspx)